精彩内容1月17日,CDE官网显示,石药集团子公司石药银湖的3类仿制药吡拉西坦注射液上市申请获得承办。吡拉西坦注射液为脑代谢改善药,2023年在中国公立医疗机构终端销售额超过5亿元。吡拉西坦注射液属于神经系统疾病药物,适用于急慢性脑血管病、脑外伤、各种中毒性脑病等多种原因所致的记忆减退及轻、中度脑功能障碍,也可用于儿童智能发育迟缓。米内网数据显示,2023年中国城市公立医院、县级公立医院、城市社区...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.